The Bionow Project of the Year Award was presented last night to a project that has demonstrated a major step forward in research and generated intellectual property or demonstrated an innovative and novel approach to a problem.
Congratulations to the Nevrargenics Durham team, CEO Prof Andy Whiting, and our colleagues in Aberdeen, Liverpool and King’s College. London. Nevrargenics Ltd is a UK-based neuroscience company spun out of Durham University, specialising in the discovery and development of novel medicines (Retinoic acid Receptor-Modulators, RAR-Ms) for Healthy Ageing and neurodegenerative diseases. The MHRA has approved the protocol to clinically investigate the effects of the lead Nevrargenics drug, Ellorarxine, in ALS/FTD, which currently has no effective intervention.
For more information on Nevrargenics please contact Professor Ehmke Pohl (Co-founder and Chief Scientific Officer. (www.nevrargenics.com).
/prod01/prodbucket01/media/durham-university/research-/research-institutes/wolfson-research-institute/60056.jpg)